Kancera

Kancera is a Swedish-based biotechnology company founded in 2010. The company is dedicated to developing a new class of small molecule drugs based on the fractalkine system. Fractalkine, a master regulator controlling immune cells and cancer cells, is key in treating acute excessive inflammation and treatment-resistant cancers. Kancera's lead drug candidate KAND567 is currently in a phase II trial to address its cardiac-protective effect following myocardial infarction. Additionally, Kancera has plans to initiate a phase I/II study of KAND567 in ovarian cancer in 2023. The company's stock is traded on the Nasdaq First North Premier Growth Market. As a biotech startup targeting the critical areas of inflammation and cancer treatment, Kancera showcases promising potential for growth and innovation in the healthcare industry.